lipid nanoparticle
Unique COVID-19 Phenotype Emerges Through Multi-Omic Patient Analysis
The researchers also developed a web-based tool based on the data they gathered that could help predict COVID-19 severity in patients.
Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.
Arcturus Therapeutics this week announced new data showing that its proprietary lipid nanoparticles are capable of functionally delivering messenger RNA into the livers of mice, which a company official said opens the door for the use of the technology with CRISPR-based drugs.
Researchers from Tekmira Pharmaceuticals last week published new data showing that siRNAs targeting Marburg virus that have been formulated with the company's lipid nanoparticles could provide up to 100 percent post-exposure protection against infection in guinea pig models.
Alnylam Pharmaceuticals researchers last month published details on the company’s efforts to improve lipid nanoparticles for RNAi drug delivery.
Mar 15, 2012
Feb 2, 2012
Jan 19, 2012
Apr 21, 2011
Jan 13, 2011
Nov 11, 2010
Aug 6, 2009